lyl797
lyell immunopharmaceutical
['lyl797', 'nct05274451']
plans for a phase 1 clinical trial (nct05274451) for lyl797, an autologous investigational ror1-targeted chimeric antigen receptor (car) t-cell therapy, which has begun screening patients, were presented at #esmo22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.